Biocytogen Pharmaceuticals (Beijing) Balance Sheet Health
Financial Health criteria checks 4/6
Biocytogen Pharmaceuticals (Beijing) has a total shareholder equity of CN¥790.4M and total debt of CN¥350.7M, which brings its debt-to-equity ratio to 44.4%. Its total assets and total liabilities are CN¥2.4B and CN¥1.7B respectively.
Key information
44.4%
Debt to equity ratio
CN¥350.74m
Debt
Interest coverage ratio | n/a |
Cash | CN¥426.14m |
Equity | CN¥790.44m |
Total liabilities | CN¥1.66b |
Total assets | CN¥2.45b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 2315's short term assets (CN¥723.1M) exceed its short term liabilities (CN¥577.6M).
Long Term Liabilities: 2315's short term assets (CN¥723.1M) do not cover its long term liabilities (CN¥1.1B).
Debt to Equity History and Analysis
Debt Level: 2315 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 2315's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2315 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 2315 has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 29.3% each year.